New Drug Aims to Erase Addiction's Lasting Imprint on the Brain

MONTPELLIER, France – January 26, 2026 – In a significant move that could reshape the landscape of addiction treatment, French biopharmaceutical company NFL Biosciences has announced a bold new strategy for its smoking cessation drug candidates, based on a deeper understanding of how they may reverse the long-term neurological damage caused by tobacco.

The company is raising its efficacy targets for two botanical drugs, NFL-101 and NFL-102, after new research elucidated a novel mechanism of action that goes far beyond managing withdrawal symptoms. Instead of simply masking cravings, the treatments appear to target and normalize the lasting neurobiological and inflammatory changes that keep smokers addicted, a concept the company calls the brain's "neuronal imprint."

This breakthrough has prompted a revised, dual-pronged clinical development plan designed to be more efficient and targeted. Bruno Lafont, CEO and Co-founder of NFL Biosciences, stated that this new understanding enables a more ambitious strategy. "This in-depth understanding of the mechanism of action of tobacco extracts as smoking cessation treatments now enables the company to deploy a more ambitious strategy, targeting higher levels of efficacy," he explained, noting the complementary roles of the two drug candidates.

Rewriting the Brain's Addiction Script

Current smoking cessation aids, such as nicotine replacement therapies (NRTs) and drugs like varenicline, primarily work by acting on nicotinic receptors to alleviate the discomfort of withdrawal. While helpful for some, their long-term success rates are limited because they don't address the fundamental changes addiction creates in brain circuitry and function. NFL Biosciences' approach is fundamentally different.

Research conducted in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA) has revealed that the company's tobacco-extract-based drugs modulate the deep-seated neurobiology of addiction. The brain of a long-term smoker doesn't simply return to normal after quitting; it remains scarred by what researchers describe as a persistent "neuroimmune context."

Nicolas Tournier, a pharmacologist and director at the CEA, elaborated on this challenge. "Smoking cessation often fails because the brain remains permanently marked by tobacco," he stated. Tournier explained that during withdrawal, several signaling pathways remain abnormally active, including CREB, a key protein in developing addiction; JNK, involved in stress response; and NF-κB, a major player in neuroinflammation. This is compounded by astrogliosis, a chronic activation of brain support cells that contributes to cravings.

This is where the new drugs diverge. Preclinical studies on mice showed that NFL-101 significantly reduces neuroinflammation. NFL-102, an enriched formulation, goes further. It was found to normalize all three overactive signaling pathways (CREB, JNK, NF-κB) and significantly reduce astrogliosis. According to Tournier, this combined effect "attenuates the neuroimmune and neuronal imprint of smoking, which goes beyond simply controlling the effects of withdrawal."

The modulation of the CREB pathway is particularly noteworthy. Independent scientific literature has increasingly identified CREB as a master regulator in the brain's reward system, playing a central role in the neuroadaptations that lead to tolerance, dependence, and relapse across multiple types of addiction.

A Two-Pronged Attack on Smoking

Armed with this new mechanistic insight, NFL Biosciences has redesigned its clinical strategy to be faster, more cost-effective, and more precise. The company is now pursuing two complementary development paths for its candidates.

NFL-101, which has already completed a Phase 2 study known as CESTO2, will be developed as a precision-medicine tool. While it showed a 24.1% continuous abstinence rate in the general study population—a result comparable to existing treatments—preliminary analysis suggests its efficacy soars to between 35% and 60% in a specific subpopulation of smokers. This group, which represents roughly one-third of the general population, appears to have characteristics that make them particularly responsive to NFL-101's anti-inflammatory action. The company plans to confirm this finding with a full analysis of the study data and develop a predictive biomarker to identify these high-responders for a streamlined and more potent Phase 3 trial. This targeted approach would significantly reduce the number of participants needed, lowering development costs and potentially accelerating its path to market.

Meanwhile, NFL-102 will be advanced as a broad-spectrum treatment for the general smoking population. Its enriched composition and more comprehensive mechanism of action, particularly its ability to normalize the CREB pathway and reduce astrogliosis, are expected to deliver superior efficacy for all smokers. NFL Biosciences plans to file for a Phase 2b clinical trial in mid-2026. This study will involve 450 participants across France to confirm efficacy, select the optimal dose, and verify safety. The study's design, with a relatively short 43-day follow-up, is also intended to control costs and facilitate recruitment.

Beyond Nicotine: A 'Universal' Addiction Treatment?

The most far-reaching implication of the company's research lies in the expanded potential of NFL-102. Because of its central role in modulating the CREB signaling pathway—a mechanism common to the neurobiology of many substance use disorders—NFL Biosciences has filed a new patent for NFL-102 that extends its intellectual property protection to 2047 and broadens its scope beyond tobacco. The new patent covers potential treatments for addiction to alcohol, psychostimulants, opioids, and cannabinoids.

This positions NFL-102 not just as a next-generation smoking cessation aid, but as a potential platform for treating a wide array of addictions that represent a staggering global public health crisis. The CREB pathway has been scientifically linked to the long-term brain changes associated with opioid dependence, cocaine and methamphetamine use, and alcohol use disorder. A treatment that could correct these underlying neuroadaptations, rather than just managing the symptoms of one specific substance, would be a monumental breakthrough.

The path forward remains challenging and requires significant investment. Clinical trials are notoriously expensive and time-consuming, and the science, while promising, must be validated in large-scale human studies. The company has stated that it will seek a strategic partner to help finance the pivotal Phase 3 trials for both drugs. Nevertheless, this refined strategy, backed by compelling science, charts a clear and ambitious course toward what could be the first treatment to truly address the enduring mark that addiction leaves on the human brain.